Neuroblastoma Australia

Lucy Jones, Founder and President Neuroblastoma Australia

Lucy Jones is the mother of Sienna and Jamie Hoffmann. Lucy is focused on driving change in survival rates through more research, having tragically lost her daughter Sienna to the illness in 2010. Sienna is the inspiration for this site and the fundraising efforts that the site promotes. When Sienna was first diagnosed, Lucy started fundraising with her friends, and this small group called 'Sienna Hoffmann and friends' raised over $725 000 for the Children’s Cancer Institute Australia. Lucy organised a number of Sienna Frangipani Gala Dinners as well as other events and founded the Neuroblastoma Run 2 Cure with friends and volunteers.

Michaela Flanagan, co-founder Neuroblastoma Australia

Michaela became involved with Neuroblastoma shortly after her daugther Ciara was diagnosed with the illness. Michaela joined forces with Lucy to establish Neuroblastoma Australia, in order to raise awareness of the illness and essential funds to invest into research for a cure. Michaela has organised four Balmain Family Fun Days in honour of Ciara, who is a flourishing little girl. These events have contributed over $300 000 to the Children’s Cancer Institute for research into Neuroblastoma.

Holly Marquette, Marketing and Events

Holly has had a career in Public Relations and Marketing for 15 years, working in various positions and industries including the not-for-profit sector, with organisations including the Sydney Children’s Hospital Foundation and Guide Dogs Victoria. Holly worked in this field until six years ago when she and her husband started, ran and owned their own successful business. She managed the bookkeeping, payroll and marketing side of the business until they sold it in late 2013. Since then, until October 2016, she has worked as an Office Manager for an accountancy firm and Donor Relations and Events Officer for Redlands school.

The Committee

Rochelle Yates, Vice President

Rochelle is a mother of two, and Chairman of a global logistics company where she specialises in marketing. Rochelle's career includes vast experience in events and promotions and she has brought this skill to help coordinate numerous fundraising events and activities for Neuroblastoma Australia.  Rochelle first became involved with Neuroblastoma in 2010 and has been committed to raising awareness of the illness and funds for research into a cure ever since. She continues this dedication in her capacity as Vice President of Neuroblastoma Australia.

Jane Price, Secretary

Jane Price holds a Bachelor of Arts and a Bachelor of Laws. She is a small business owner, running her own immigration consultancy business, which she has grown in a few short years into a thriving practice with a couple of employees. Jane is lucky enough to have a “pidgeon-pair” of children (aged 11 & 14) and was also privileged to know Sienna Hoffman, the inspiration for Neuroblastoma Australia, since just before her diagnosis. Jane has supported most of the Neuroblastoma Australia events since 2010 and looks forward to playing a more active role in the charity going forwards.

Sarah Jones

Passionate about working with children, Sarah is a mum of three with a teaching qualification, who is currently pursuing postgraduate studies in Special Education. Sarah has experience in the not-for-profit sector, having worked for many years at The Starlight Children’s Foundation helping to develop in-hospital entertainment programs for seriously ill children.  Sarah has been involved with fundraising for research into Neuroblastoma for over 5 years and has an unwavering dedication to raising awareness of the illness. 

Louise Causer, Medical advisor

Louise is a medical epidemiologist and lecturer currently based at The Kirby Institute, UNSW Australia and has worked internationally both in clinical and research settings across a number of fields. Having trained and working in a highly academic setting for the past decade, Louise has direct experience and key insight into the research setting in Australia and internationally and her expertise will support decision making around the award of funds raised by Neuroblastoma Australia. She is committed to help ensure the limited resources raised are utilised to fund key research of the highest quality. Louise is a mother of 4. She joined the board of Neuroblastoma Australia in September 2016.  Qualifications: MBBS (University of Sydney), MScPH & DTM&H (London School of Hygiene and Tropical Medicine), PhD (UNSW)

Isabella Mannix

Isabella has a background in Marketing and Sales, with twenty years’ experience working in a variety of senior roles within the Financial Services sector and more recently the Health sector.  After her daughter Georgia was diagnosed with Stage 1 Neuroblastoma in 2012, Isabella and her family have supported various childrens’ cancer charities – including the Childrens’ Cancer Institute, the Kids Cancer Project, Redkite and Neuroblastoma Australia.   Isabella is hopeful that one day all children who are diagnosed with Neuroblastoma have the same positive outcome as her daughter, who is now almost five years in remission.

Sally Paterson

Sally Paterson is a freelance writer with over 15 years experience crafting content and conveying messages for a vast range of clients and a broad reaching audience. From sole traders to blue chip companies, advertisements to full features, The Age to The Sydney Morning Herald, her skills lie in defining the message, and telling the story. A mother of three, she first learned of the devastating effect of neuroblastoma in 2006, and has been committed to assisting with fundraising and increasing awareness ever since.

Claire Mulae

Claire Mulae has been involved with the Neuroblastoma cause since 2010 when she first met Lucy during a baby class. After hearing Lucy and Sienna’s story she joined the Sienna Hoffman committee and helped coordinate fundraising activities including three gala dinners. Claire is a coach, counsellor and author, she has been working in the professional and personal development industry for 13 years. Claire hopes Neuroblastoma Australia will provide vital funds to end the suffering caused by this terrible disease.

We are delighted to have the support of Children’s Cancer Institute and Sydney Children’s Hospital Randwick.

Michelle Haber AM [AM, BSc (Psych) (Hons), PhD, Hon DSc UNSW]

Professor Haber joined CCIA as a staff scientist in 1984. Professor Haber was appointed Director of CCIA in June 2000 and Executive Director in 2003. Professor Haber is known for her world-class research into the treatment of neuroblastoma and acute lymphoblastic leukaemia in children.

Professor Haber holds a conjoint appointment as Professor in the Faculty of Medicine at the University of New South Wales. She is the current President of the International Advances in Neuroblastoma Research Association, and in 2007, was appointed a Member of the Order of Australia for services to science in the field of research into childhood cancer, to scientific eduction, and to the community. In 2008, she was awarded an Honorary Doctorate from the University of New South Wales for her eminent service to the cancer research community.

Professor Glenn Marshall [MBBS, MD UNSW, FRACP]

Professor Marshall has been Head of the Molecular Carcinogenesis Program at CCIA since 1995. His primary pre-clinical research interests include investigating the mechanisms by which normal embryonal cells become cancerous, and improving the effectiveness of non-cytotoxic anticancer therapy in child cancer.

He is currently co-chair of the Australian and New Zealand Children’s Haematology and Oncology Group (ANZCHOG) ALL Study VIII. In addition to his research activities, Professor Marshall is a full time Paediatric Haematologist and Oncologist, and Director of the Centre for Children’s Cancer and Blood Disorders at Sydney Children’s Hospital. He has authored more than 100 papers in peer reviewed scientific journals.

Professor Murray Norris [BSc ANU, MAppSc NSWIT, PhD UNSW]

Professor Norris was one of the first three scientists to staff CCIA when its research laboratories opened in 1984. He is Head of the Molecular Diagnostics Program and was appointed Deputy Director of CCIA in 2000. His research interests focus on utilising new molecular genetic technologies to improve the diagnosis and risk classification and treatment of childhood cancer, and he has been responsible for developing and implementing unique technology enabling the early prediction of relapse in children with Acute Lymphoblastic Leukaemia.

Professor Norris has an international research reputation in childhood neuroblastoma, particularly with regard to the molecular analysis of genes and their relationship with clinical variables. He has spent over 15 years investigating childhood cancers at the molecular level and has undertaken extensive research into the characterisation of genes involved in mediating resistance to chemotherapeutic drugs in paediatric leukaemia and neuroblastoma. The development of new therapeutic approaches to treating cancers and the detection of minimal residual leukaemia are key areas of his research.

Professor Norris has published over 100 peer-reviewed papers and is a regular reviewer for several national and international grant-funding bodies as well as numerous international journals. In addition to an established record of state and national grant-funded research, the quality of his work has been recognised by a number of awards.

Dr David Ziegler [BSc ANU, MAppSc NSWIT, PhD UNSW]

Dr Ziegler is a paediatric oncologist (cancer specialist) at Sydney Children’s Hospital and conducts research at Children’s Cancer Institute Australia (CCIA). He is the head of the clinical trials unit within the Cancer Centre at the hospital and is in the process of establishing an early phase clinical trials program to test new therapies in children with incurable disease.

His strategy is to develop the capacity to rapidly translate positive laboratory findings into clinical trials via the hospital’s early phase clinical trials unit. This will facilitate the creation of new treatments for children who have no other effective treatment options available.

Following his research at Harvard Medical School, Dr Ziegler joined CCIA’s research team and was awarded the 2010 Balnaves Foundation grant.

RESEARCH NEWS: Burtomab has just been designated by the US Food and Drug Administration as a breakthrough drug for children with relapsed or refractory neuroblastoma with central nervous system or leptomeningeal metastasis. This will speed up the time it takes to make this therapy available to the children. Currently there are no drugs available to treat this type of advance neuroblastoma. For more details see: tinyurl.com/y8x37yue ...

Neuroblastoma Australia
Ste 3, 165 Sailors Bay Rd
Northbridge NSW 2063
0406 991 606
info@nb.org.au
Neuroblastoma Australia Incorporated is a registered charity with GDR Status . ABN 74 173 375 414.